Currently, the EGFR inhibitor gefitinib is a first-line intervention for patients with advanced non-small cell lung cancer (NSCLC), but a prevalent problem is the occurrence of TKI resistance (Raez et al., 2022). This evidence concerns the gene EGFR and non-small cell lung carcinoma.